PMID: 9529050Apr 7, 1998Paper

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans

Infection and Immunity
Bjørn HanebergJ Holst

Abstract

A nasal vaccine, consisting of outer membrane vesicles (OMVs) from group B Neisseria meningitidis, was given to 12 volunteers in the form of nose drops or nasal spray four times at weekly intervals, with a fifth dose 5 months later. Each nasal dose consisted of 250 microg of protein, equivalent to 10 times the intramuscular dose that was administered twice with a 6-week interval to 11 other volunteers. All individuals given the nasal vaccine developed immunoglobulin A (IgA) antibody responses to OMVs in nasal secretions, and eight developed salivary IgA antibodies which persisted for at least 5 months. Intramuscular immunizations did not lead to antibody responses in the secretions. Modest increases in serum IgG antibodies were obtained in 5 volunteers who had been immunized intranasally, while 10 individuals responded strongly to the intramuscular vaccine. Both the serum and secretory antibody responses reached a maximum after two to three doses of the nasal vaccine, with no significant booster effect of the fifth dose. The pattern of serum antibody specificities against the different OMV components after intranasal immunizations was largely similar to that obtained with the intramuscular vaccine. Five and eight vaccinees in t...Continue Reading

References

Feb 1, 1994·Archives of Otolaryngology--head & Neck Surgery·B Winther, D J Innes
Sep 1, 1996·The Journal of Infectious Diseases·R L Ward

❮ Previous
Next ❯

Citations

Jun 3, 2009·Expert Review of Vaccines·Susan LewisAndrew J Pollard
Mar 2, 2011·Canadian Journal of Microbiology·Belkis RomeuOliver Pérez
Nov 5, 2010·Journal of Drug Targeting·Inderjit Jabbal-Gill
Feb 6, 2013·Pharmaceutical Development and Technology·Can ÇokçalışkanSevda Şenel
Apr 27, 2000·The Pediatric Infectious Disease Journal·A J Pollard, M Levin
Aug 7, 2003·Expert Review of Vaccines·Bjørn Haneberg, Johan Holst
Oct 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Victoria DavenportRobert S Heyderman
Dec 2, 2005·Expert Opinion on Biological Therapy·Kirsten P Perrett, Andrew J Pollard
Jul 29, 2005·Immunological Reviews·Per Brandtzaeg, Finn-Eirik Johansen
Aug 6, 2008·Infection and Immunity·Stefan SchildAndrew Camilli
May 24, 2005·Drugs·Ram Yogev, Judith Guzman-Cottrill
Apr 23, 2016·Scientific Reports·Nancy L PriceMario F Feldman
May 3, 2001·The New England Journal of Medicine·N E RosensteinJ M Hughes
Sep 14, 2002·Infection and Immunity·Libuse JanakovaBjørn Haneberg
Mar 22, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Oh Youn KimYong Song Gho
Nov 13, 2008·Infection and Immunity·Stefan SchildAndrew Camilli
Jul 26, 2005·Infection and Immunity·Karen RobinsonDlawer A A Ala'Aldeen
Nov 16, 2012·Expert Review of Vaccines·Ayman GebrilValerie A Ferro
Feb 12, 2015·Helicobacter·Lorinda TurnerRichard L Ferrero
Jul 19, 2003·Scandinavian Journal of Immunology·H Jakobsen, I Jonsdottir
Aug 15, 2003·Journal of Peptide Science : an Official Publication of the European Peptide Society·Ross P McGearyIstvan Toth
Jul 6, 2012·FEMS Immunology and Medical Microbiology·Soma MitraHemanta Koley
Jul 18, 2018·Frontiers in Immunology·Lorinda TurnerMaria Kaparakis-Liaskos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.